FSD Pharma (CVE:HUG – Get Free Report)‘s stock had its “buy-venture” rating reissued by Singular Research in a research note issued to investors on Tuesday, Zacks.com reports. Singular Research also issued estimates for FSD Pharma’s Q1 2024 earnings at ($0.07) EPS, Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.16) EPS.
FSD Pharma Stock Performance
FSD Pharma (CVE:HUG – Get Free Report) last announced its quarterly earnings results on Thursday, March 28th. The company reported C($0.05) EPS for the quarter.
Recommended Stories
- Five stocks we like better than FSD Pharma
- What Are Dividend Champions? How to Invest in the Champions
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What are earnings reports?
- Generac Powers Ahead on the Electrification Mega-Trend
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
